Motor benefits for prasinezumab in rapidly progressing early-stage PD
Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, has shown promise for slowing motor progression in patients with rapidly progressing Parkinson’s disease in a post-hoc analysis of the PASADENA phase 2 study.
